Thanks much for sharing the paper on the machine learning approach and the wonderful presentation, Toby!
1. I have no more additions for the stakeholders to the colleagues’ discussions previously. This should just be patient-centric perspectives in applying machine learning to symptom prediction. I would love to focus on regulatory bodies and ethical committees that play a critical role in overseeing the machine learning models in healthcare. In addition to ensuring the health and data protection regulations, I consider these stakeholders should also be guided on the best practices in conducting the model with thorough reviews, which will also uphold the integrity of the research and maintain public trust.
2. I would consider simply that the machine learning model should be interpretable so that clinicians and patients can understand easily and trust the predictions. As discussed in the seminar, it should include diverse and representative data in the training process. If the model was trained predominantly on data from common cancer types, it may not accurately predict symptoms for patients with rare cancers, leading to disparities in care and outcomes.